Hepatitis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anemia Therapy
Investigators at California Pacific Medical Center target anemia therapy
August 6th, 2007
New research, "Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study," is the subject of a report. "Pegylated interferon plus ribavirin can cause dose-limiting anemia. Taribavirin, a ribavirin prodrug, has shown a lower incidence of anemia," scientists writing in the Journal of Hepatology report. "We sought to determine the efficacy and safety of taribavirin vs. ribavirin combined with pegylated interferon in patients with chronic hepatitis C (CHC). This phase 2 open-label study randomized 180 patients with CHC...
Source: Hepatitis Weekly (2007-08-06)
|
